China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced receiving a financial pledge of BRL130 million (USD23 million) from the Brazilian government as part of the Parcerias para o Desenvolvimento Produtivo (PDP). This initiative, co-promoted by domestic companies in Brazil and Brazilian Ministry of Health affiliated enterprises, aims to secure the basic drug supply in Brazil with a focus on insulin glargine production.
Annual Production Capacity and Impact
The project is designed to achieve an annual production capacity of 70 million doses, marking a significant milestone in insulin production in South America. By localizing the entire industry chain, Brazil aims to enhance its pharmaceutical self-sufficiency and reduce reliance on imported insulin products.-Fineline Info & Tech
Leave a Reply